Eli Lilly and Co. (NYSE: LLY), known as one of the powerhouses in the pharmaceutical industry, has just been given another boost by a key analyst. Credit Suisse sees solid upside in this company as the result of a strong pipeline, with its Alzheimer’s candidate as a potential blockbuster.

Credit Suisse upgraded Eli Lilly to an Outperform rating from Neutral and raised its price target to $105 from $89, implying an upside of 22% from current prices. This valuation was driven by higher Jardiance estimates and higher probability-adjusted sales for several pipeline assets, most notably abemaciclib, anti-CGRP and baricitinib. Accordingly, Credit Suisse raised its EPS estimates to $3.30, $3.58 and $4.10 from $3.25, $3.49 and $3.89 for 2015 through 2017, respectively.

The brokerage firm’s proprietary doctor survey highlights how the impressive EMPA-REG OUTCOME results should boost Jardiance sales and how the high degree of awareness of the results already (especially among specialists) should allow for this upside to come sooner than expected.

The company’s diverse, relatively de-risked mid-late stage pipeline is encouraging. It also includes several attractive medium-large sized opportunities that Credit Suisse believes are underappreciated as investors focus more on the two potentially transformative but higher-risk options in solanezumab (Alzheimer’s) and evacetrapib (cholesterol).

ALSO READ: UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Ultimately, the survey showed most physicians (especially endocrinologists) are already well aware of the mortality benefit demonstrated by Jardiance in EMPA-REG OUTCOME. Credit Suisse believes this should allow for increased use of Jardiance (and other SGLT-2s) even in the near term, with further upside likely in 2017 and beyond once the data from the study are included in the Jardiance package insert.

Much of the investor focus on Eli Lilly is naturally on the two late-stage assets solanezumab and evacetrapib that could potentially transform the company. Credit Suisse is cautiously optimistic on both but believes investors are still underappreciating several other attractive assets that at this point are relatively de-risked, based on data Eli Lilly or competitors have released. These include baricitinib (rheumatoid arthritis), ixekizumab (psoriasis), anti-CGRP (migraine) and abemaciclib (oncology), all of which also have multi-billion-dollar potential, but where consensus expectations are generally well below that level.

Shares of Eli Lilly were up 2.7% at $86.01 on Friday morning. The stock has a consensus analyst price target of $93.61 and a 52-week trading range of $60.58 to $92.85. The company has outperformed both the S&P and its peers, and Oppenheimer sees a high probability of further outperformance ahead.

ALSO READ: Why Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.